Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.

James LambertMariana LamacieBabitha ThampinathanMustafa A AltahaMaryam EsmaeilzadehMark NolanCamila Urzua FresnoEmily SomersetEitan AmirThomas H MarwickBernd J WinterspergerPaaladinesh Thavendiranathan

Published in: Heart (British Cardiac Society) (2020)

Temporal changes in 3D-LVEF, 2D-GLS and CMR LVEF in patients with CTRCD had the least overlap with the variability in healthy volunteers; however, 2D-GLS appears to be the most suitable for clinical application in individual patients.

Keyphrases

cancer therapy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
magnetic resonance imaging
computed tomography
drug delivery
left ventricular
prognostic factors
pulmonary hypertension
contrast enhanced
magnetic resonance
patient reported
label free
sensitive detection